Taiwan · Delayed Price · Currency is TWD PharmaEngine Statistics
Total Valuation
PharmaEngine has a market cap or net worth of TWD 7.70 billion. The enterprise value is 2.77 billion.
| Market Cap | 7.70B |
| Enterprise Value | 2.77B |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | Aug 13, 2025 |
Share Statistics
PharmaEngine has 143.68 million shares outstanding. The number of shares has decreased by -0.20% in one year.
| Current Share Class | 143.68M |
| Shares Outstanding | 143.68M |
| Shares Change (YoY) | -0.20% |
| Shares Change (QoQ) | -0.24% |
| Owned by Insiders (%) | 1.23% |
| Owned by Institutions (%) | 6.39% |
| Float | 93.45M |
Valuation Ratios
The trailing PE ratio is 18.24 and the forward PE ratio is 19.42.
| PE Ratio | 18.24 |
| Forward PE | 19.42 |
| PS Ratio | 7.99 |
| PB Ratio | 1.52 |
| P/TBV Ratio | 1.52 |
| P/FCF Ratio | 43.22 |
| P/OCF Ratio | 43.15 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.82, with an EV/FCF ratio of 15.52.
| EV / Earnings | 6.55 |
| EV / Sales | 2.87 |
| EV / EBITDA | 5.82 |
| EV / EBIT | 5.93 |
| EV / FCF | 15.52 |
Financial Position
The company has a current ratio of 29.16, with a Debt / Equity ratio of 0.01.
| Current Ratio | 29.16 |
| Quick Ratio | 28.98 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.08 |
| Debt / FCF | 0.22 |
| Interest Coverage | 1,453.49 |
Financial Efficiency
Return on equity (ROE) is 8.00% and return on invested capital (ROIC) is 188.39%.
| Return on Equity (ROE) | 8.00% |
| Return on Assets (ROA) | 5.19% |
| Return on Invested Capital (ROIC) | 188.39% |
| Return on Capital Employed (ROCE) | 9.15% |
| Weighted Average Cost of Capital (WACC) | 5.19% |
| Revenue Per Employee | 21.42M |
| Profits Per Employee | 9.39M |
| Employee Count | 45 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 2.81 |
Taxes
In the past 12 months, PharmaEngine has paid 129.58 million in taxes.
| Income Tax | 129.58M |
| Effective Tax Rate | 23.47% |
Stock Price Statistics
The stock price has decreased by -40.38% in the last 52 weeks. The beta is 0.17, so PharmaEngine's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -40.38% |
| 50-Day Moving Average | 56.70 |
| 200-Day Moving Average | 65.77 |
| Relative Strength Index (RSI) | 38.41 |
| Average Volume (20 Days) | 439,746 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEngine had revenue of TWD 963.83 million and earned 422.55 million in profits. Earnings per share was 2.94.
| Revenue | 963.83M |
| Gross Profit | 909.13M |
| Operating Income | 466.57M |
| Pretax Income | 552.13M |
| Net Income | 422.55M |
| EBITDA | 468.71M |
| EBIT | 466.57M |
| Earnings Per Share (EPS) | 2.94 |
Balance Sheet
The company has 4.98 billion in cash and 39.96 million in debt, with a net cash position of 4.94 billion or 34.35 per share.
| Cash & Cash Equivalents | 4.98B |
| Total Debt | 39.96M |
| Net Cash | 4.94B |
| Net Cash Per Share | 34.35 |
| Equity (Book Value) | 5.06B |
| Book Value Per Share | 35.24 |
| Working Capital | 5.04B |
Cash Flow
In the last 12 months, operating cash flow was 178.47 million and capital expenditures -280,000, giving a free cash flow of 178.19 million.
| Operating Cash Flow | 178.47M |
| Capital Expenditures | -280,000 |
| Depreciation & Amortization | 2.14M |
| Net Borrowing | -8.67M |
| Free Cash Flow | 178.19M |
| FCF Per Share | 1.24 |
Margins
Gross margin is 94.32%, with operating and profit margins of 48.41% and 43.84%.
| Gross Margin | 94.32% |
| Operating Margin | 48.41% |
| Pretax Margin | 57.29% |
| Profit Margin | 43.84% |
| EBITDA Margin | 48.63% |
| EBIT Margin | 48.41% |
| FCF Margin | 18.49% |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 3.73%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 3.73% |
| Dividend Growth (YoY) | 300.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 203.98% |
| Buyback Yield | 0.20% |
| Shareholder Yield | 3.97% |
| Earnings Yield | 5.49% |
| FCF Yield | 2.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2017. It was a forward split with a ratio of 1.1999616012.
| Last Split Date | Jul 26, 2017 |
| Split Type | Forward |
| Split Ratio | 1.1999616012 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |